Gilead names Kevin Young new chief operating officer
pharmafile | May 25, 2016 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Gilead
Gilead Sciences (NASDAQ: GILD) has announced two new senior appointments, including Kevin Young as its new chief operating officer.
Martin Silverstein also joins the senior team at Gilead as the new executive vice president, strategy. Both men will report to John F. Milligan, president and chief executive officer. In the same announcement, Gilead revealed that Paul R. Carter, executive vice president, commercial operations, has left the company.
As COO, Young will assume responsibilities for the company’s worldwide commercial organisation, facilities and operations. From 2004 to 2014, he served as executive vice president of commercial operations. Since then, he has held the role of senior advisor. Previously, he held roles at ICI Pharmaceuticals and Amgen. He holds undergraduate and postgraduate degrees from Liverpool and Nottingham. In 2011, Young was awarded a CBE for his services to the healthcare and pharmaceutical industries.
Milligan says: “I am delighted to welcome Kevin back to Gilead in a full-time capacity. His contributions during his previous tenure, particularly his management of the introduction of eight novel therapies across diverse geographies, made a tremendous impact on the company. I have equally valued his continued engagement and significant contributions as an advisor to Gilead over the past two years.
“Kevin’s knowledge of Gilead’s business, all aspects of commercial operations and our therapeutic areas of focus, his commitment to operational excellence, and his leadership capabilities make him an obvious choice for the role of Chief Operating Officer.”
Dr Silverstein, meanwhile, will oversee the company’s corporate development, commercial planning and alliance management functions. He previously held roles at Anthem and the Boston Consulting Group. He received a medical degree from Yale, an MBA from Harvard Business School and a bachelor’s degree from University of Pennsylvania.
Milligan comments: “I’m very pleased to welcome Marty to the Gilead team. His vast expertise in the healthcare sector, across biopharmaceuticals, pharmacy benefit management, health insurance and healthcare delivery, will be of great value to Gilead as we see the complexity of our business increase around the world. I’m looking forward to working with Marty and the rest of the company’s senior leadership team to deliver continued growth and bring more medicines to more people around the world.”
The company, known for its hepatitis C drugs, is fighting growing competition for its key products, Harvoni and Sovaldi, in this area. They also have several late-stage drugs in their pipeline, including treatments for AIDS, liver disease and oncology treatments.
Related Content
Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …
Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …
Gilead shares phase 3 results from HIV prevention trial
Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE …
